KAMADA LTD

Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, which is the gold standard for measuring rabies-neutralizing antibodies. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, significantly expands Kamada's advanced testing capabilities for its leading Anti-Rabies products, KEDRAB® and KAMRAB®, which generated over $70 million in sales in 2025. The new lab is expected to enhance operational efficiencies and reinforce the company's commitment to quality and scientific excellence.

Kamada Ltd. announced FDA approval for its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory, located at its Beit Kama, Israel plant. This state-of-the-art facility, also approved by Health Canada and the Israeli Ministry of Health, significantly expands the company's advanced testing capabilities for Anti-Rabies potency in the manufacturing of KEDRAB® and KAMRAB®. The new lab is expected to drive increased operational efficiencies and reinforces Kamada's commitment to innovation and quality, supporting products that generated over $70 million in sales in 2025.

Kamada Ltd. announced it will release its financial results for the first quarter ended March 31, 2026, before the U.S. financial markets open on Wednesday, May 13, 2026. Following the release, Kamada management will host an investment community conference call on the same day at 8:30 AM Eastern Time to discuss these results and answer questions.